Actively Recruiting
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
Led by Fujian Medical University Union Hospital · Updated on 2026-05-14
405
Participants Needed
1
Research Sites
213 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chemoresistance in acute myeloid leukemia (AML) is closely associated with the bone marrow microenvironment. Elevated levels of IL-6, leptin, fumarate, and other factors within the bone marrow microenvironment have been shown to enhance oxidative phosphorylation or antioxidant capacity in AML cells, thereby inducing chemoresistance. To explore their potential as prognostic biomarkers or therapeutic targets, this study plans to enroll 405 newly diagnosed AML patients meeting the criteria of the Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (2023 Edition), along with 81 sex- and age-matched healthy controls. By analyzing the levels of IL-6, leptin, fumarate, and other factors in patient bone marrow supernatant, we will evaluate their associations with treatment response (primary endpoints: overall survival \[OS\] and overall response rate \[ORR\] after one cycle of chemotherapy) and prognosis. Furthermore, patient-derived xenograft (PDX) mouse models established from primary AML cells will be used to validate their roles in chemoresistance, aiming to provide a basis for therapies targeting the bone marrow microenvironment.
CONDITIONS
Official Title
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis follows the Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)
- First onset of acute myeloid leukemia without prior chemotherapy
- Participation with family members and signed informed consent
You will not qualify if you...
- Presence of other malignancies requiring treatment
- Infectious diseases including SARS, viral hepatitis, or HIV/AIDS
- Major surgery within the last 21 days
- Performance Status score greater than 3
- Severe liver or kidney dysfunction or serious infection
- Severe psychiatric conditions affecting understanding or voluntary withdrawal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Actively Recruiting
Research Team
H
Huifang Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here